Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Sumida

Orthopaedic Surgery Arlington, VA Medical Doctor

NPI 1578581369 CMS profile 70628

1635 N George Mason Dr, Suite 310, Arlington, VA 22205

Open in the dashboard

General payments

$3,596

42 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Sumida of Arlington, VA is reported in the CMS Open Payments database as having received $3,596 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $149 1
2023 General $1,822 23
2022 General $1,296 4
2021 General $39 1
2020 General $52 3
2019 General $238 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Sumida
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Kevin Sumida were reported at $149. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Kevin Sumida Orthopaedic Surgery median Middle half National median
2019 $238 $644 $140–$2,844 $163
2020 $52 $312 $75–$1,860 $114
2021 $39 $520 $117–$2,495 $132
2022 $1,296 $598 $128–$2,731 $149
2023 $1,822 $461 $128–$2,264 $160
2024 $0 $497 $134–$2,475 $164
2025 $149 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supreme Orthopedic Systems, LLC $1,898 7 payments
  2. Arthrex, Inc. $1,098 15 payments
  3. Smith+Nephew, Inc. $236 4 payments
  4. DePuy Synthes Sales Inc. $66 2 payments
  5. Ferring Pharmaceuticals Inc. $50 2 payments
  6. Stryker Corporation $42 2 payments
  7. Flexion Therapeutics, Inc. $37 1 payment
  8. Ethicon US, LLC $26 1 payment
  9. Fidia Pharma USA Inc. $24 1 payment
  10. Bioventus LLC $23 1 payment
  11. Other $95 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $1,350 2 payments
  2. Food and Beverage $1,261 36 payments
  3. Travel and Lodging $985 4 payments
Products named General payments · program years 2019–2025
  1. Bone Anchors with Arthroscopic Delivery System $149 1 payment
  2. HEALICOIL $149 1 payment
  3. EUFLEXXA $50 2 payments
  4. TRIGEN INTERTAN $46 1 payment
  5. MAKO $42 2 payments
  6. NA $39 1 payment
  7. TFN-Advance $39 1 payment
  8. Fibulink $39 1 payment
  9. Zilretta $37 1 payment
  10. RIGIDLOOP $27 1 payment
  11. Other $363 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

103

Median for Orthopedic Surgery: 203

Drug cost

$1,564

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 59 $1,447
Meloxicam Generic 30 $69
Prednisone Generic 14 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$173,761

Of which drugs: $31,404

Medicare patients

501

Average age 76

Services billed

6,340

322 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Ischemic heart disease 26%
Osteoporosis 25%
Diabetes 19%
Chronic kidney disease 18%
Depression 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 29 40 $21,307
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 170 815 $616
Injection, methylprednisolone acetate, 1 mg J1010 Office 57 2,920 $295
Injection, methylprednisolone acetate, 40 mg J1030 Office 33 34 $151

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record